|
|
12 Health Care Stocks Moving In Tuesday's Intraday Session
|
|
|
|
Reported Earlier: Edesa Biotech Reports Phase 3 Data Show Paridiprubart Cuts 28-Day Mortality To 24% From 33% Across 278 Patients; Targeting Sepsis, Acute Kidney Injury And Pneumonia With New Patent Filings
|
|
|
|
Edesa Biotech shares are trading higher after the company announced additional data from a Phase 3 study of paridiprubart.
|
|
|
|
Edesa Biotech Announces Additional Data From Phase 3 Study Of Paridiprubart
|
|
|
|
Edesa Biotech Q1 EPS $(0.28) Beats $(0.45) Estimate
|
|